Is Strides Pharma overvalued or undervalued?

As of 15 September 2025, Strides Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 21.72, an EV to EBITDA of 11.84, and a ROE of 26.67%.
In comparison to peers, Strides Pharma's PE ratio is lower than Sun Pharma's 33.52 and Divi's Lab's 69.55, which are categorized as expensive, while it is slightly higher than Dr. Reddy's Labs at 19.12 and Cipla at 23.18, both of which are deemed attractive. Notably, Strides Pharma has outperformed the Sensex significantly over the past three years, with a return of 461.18% compared to the Sensex's 36.46%, reinforcing its competitive position in the market.